Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06321744
Other study ID # 2023/825
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 2024
Est. completion date December 2024

Study information

Verified date December 2023
Source Centre Hospitalier Universitaire de Besancon
Contact Quentin JACQUINOT, Dr
Phone 0370632058
Email qjacquinot@irfc-fc.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a non-randomized, non-controlled feasibility study which will take place at the Besançon University Hospital in the conventional hospitalization department. It will be carried out with patients hospitalized in the conventional hospitalization department of the medical oncology department of Besançon University Hospital. At entry, after presenting the study and obtaining non-opposition from patients, an initial assessment will be carried out before the APA program. This assessment will include an evaluation of physical parameters (measurements of body composition, functional capacities, autonomy in activities of daily living and muscular strength), as well as an evaluation of quality of life relating to health and motivation to practice physical activity. At the end of the initial assessment, an APA program supervised (individually and in a room) by an APA teacher will be offered to patients. The sessions will be offered daily to patients (maximum 5 times/week). They will last on average 20 minutes each depending on the fatigue, pain and fitness of the patients. The objectives pursued are mainly an improvement in functional independence and mobility.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Man or woman aged 18 and over (no age limit) - Patient followed for cancer, - Patients with no medical contraindication to adapted physical activity (certificate) - Patient with a performance index status less than 4 - Patient hospitalized in the conventional medical oncology hospitalization department of Besançon University Hospital. - Patient not opposed to participating in the study - Patient affiliated to a French social security scheme or beneficiary of such a scheme. - For women: menopausal for at least 24 months, surgically sterilized, or, for women of childbearing age, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, patches contraceptives) - Length of hospitalization estimated at at least 7 days (main objective) and with the patient's objective of returning home or to SSR in the long term Exclusion Criteria: - Patient with an absolute medical contraindication to adapted physical activity - Patient with inability to understand instructions and complete questionnaires. - Patient with a performance index status of 4 - Patient with legal incapacity or limited legal capacity - Patient unlikely to cooperate in the study and/or low cooperation anticipated by the investigator - Patient without health insurance - Pregnant woman - Patient being in the exclusion period of another study or provided for by the "national volunteer file".

Study Design


Related Conditions & MeSH terms


Intervention

Other:
adapted physical activity program (APA Program)
Content of the APA program: Strengthening of the lower limbs: Exercises alternating different regimes of muscular contractions (eccentric, concentric and isometric), with the use of elastics, balls or even body weight. These exercises will mainly work the quadriceps and hamstrings. Upper limb strengthening: Exercises focused on eccentric and concentric contraction regimes, in a global movement approach (as opposed to a segmental approach), with the use of elastics, dumbbells, weighted balls, etc. These exercises will work the muscles of the biceps, triceps, pectorals, deltoids and lats. Walking: In the room and/or in the corridor, with technical assistance (cane/walker, etc.) or human work Balance and proprioception: Balance work in a bi- and uni-pedal situation, statically and dynamically (eyes open and closed) will be offered with the use of proprioception boards and/or mats combining if possible work in dual task.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Besancon

Outcome

Type Measure Description Time frame Safety issue
Primary Validate the feasibility of a supervised adapted physical activity (APA) program during the first 7 days of hospitalization in medical oncology for patients with cancer undergoing treatment The main objective of the study is to validate that the proportion of patients having completed, from inclusion (D0), at least three supervised APA sessions of a minimum duration of 15 minutes, during the first 7 consecutive days of his hospitalization (P) is beyond a threshold considered uninteresting of 50% (P0)
To test the following hypotheses:
H0: a compliant patient rate <= 50% is uninteresting (P<=P0) H1: a compliant patient rate > 80% is expected (P>P1) With an A'Hern type design, a one-sided alpha risk of 2.5% and a power of 90%, it is required to include 28 evaluable patients in the study to test H0 vs H1.
Considering a rate of unevaluable patients of 10% it will be necessary to include 32 patients.
Hypothesis H0 will be rejected if 20 (71.4%) or more than 20 patients out of the first 28 evaluable are compliant.
7 days after inclusion
Secondary Describe the evolution of body composition measured by impedancemetry fat-free mass index and muscle mass,
body protein content,
metabolic activity index
At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Describe the evolution of physical parameters functional capacities - Score of Short Physical Performance Battery Test (Score of 0 =Faible performance to 12= Haute performance) At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Describe the evolution of autonomy in daily life activities IADL Questionnaire IADL score 0 to 4
IADL score = 0: dependent
IADL score = 4 autonomous
At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Describe the evolution of muscular strength Handgrip :results in kilograms At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Describe the evolution of the quality of life QLQ-C30 questionnaire All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Describe the evolution of motivation to practice physical activity Questionnaire BREQ-2 The BREQ-2 is a 19 item questionnaire that measures the stages of the self-determination continuum with respect to motivation to exercise with a 5 point Likert scale (0=not true for me, 4=very true for me) At inclusion (day 1) and at the study completion, an average of 15 days
Secondary Tolerance with the APA program on perception of effort Perception of effort with te Borg scale CR10.
Scale of 0 (No exertion at all) to 10 (representing an extreme intensity of activity)
immediately after each intervention session
Secondary Tolerance with the APA program on pain and fatigue Visual analog scale (0 = no pain and 10 = very severe pain) Immediately before and after each intervention session
Secondary Tolerance with the APA program on fatigue Visual analog scale (0 = no fatigue and 10 = very severe fatigue) Immediately before and after each intervention session
Secondary Compliance with the APA program Number of sessions carried out out of the number planned at the study completion, an average of 15 days
Secondary Criteria/reasons for non-participation, non-compliance, discontinuation of the intervention and study withdrawals at the study completion, an average of 15 days
Secondary Patient satisfaction Likert scale (0= unsatisfiedt o 5 =very satisfied) at the study completion, an average of 15 days
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients